Lifetime adiposity and risk of pancreatic cancer in the NIH-AARP Diet and Health Study cohort (original) (raw)

Abstract

Background: The association of excess body weight across a lifetime with pancreatic cancer has not been examined extensively. Objective: We determined the association for body mass index (BMI) at different ages and adiposity duration and gain with incident pancreatic adenocarcinoma in the NIH-AARP Diet and Health Study cohort. Design: Participants aged 50-71 y completed questionnaires at baseline (1995)(1996) and 6 months later that queried height and weight history. We calculated HRs and 95% CIs by using Cox proportional hazards models adjusted for age, smoking, sex, and intakes of energy and total fat. Results: Over an average follow-up of 10.5 y, 1206 and 2122 pancreatic cancer cases were identified in the subcohort who completed the second questionnaire (n = 273,975) and the baseline cohort (n = 501,698), respectively. Compared with normal weight, overweight or obesity at ages 18, 35, 50, or .50 y (baseline BMI) was significantly associated with pancreatic cancer, with HRs ranging from 1.15 to 1.53. A longer duration of BMI (in kg/m 2 ) .25.0 was significantly associated with pancreatic cancer (overall HR per 10-y increment of duration: 1.06; 95% CI: 1.02, 1.09), with individuals who reported diabetes having the greatest risk (HR per 10-y increment of duration: 1.18; 95% CI: 1.05, 1.32; P-interaction = 0.01) and rates. A substantial gain in adiposity (.10 kg/m 2 ) after age 50 y was significantly associated with increased pancreatic cancer risk. The etiologic fraction of pancreatic cancer explained by adiposity at any age was 14% overall and 21% in never smokers. Conclusion: Overweight and obesity at any age are associated with increased pancreatic cancer.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (54)

  1. P-trend 5 0.14 0.003 Continuous, per 10 y 1062/2,327,086 144/201,733 48.4 (45.4, 51.3) 71.4 (59.7, 83.1)
  2. 1 All analyses were limited to the subcohort of 273,977 participants and 1206 pancreatic cancer cases. OWY, overweight years.
  3. Sex-adjusted, age-standardized incidence rates per 100,000 person-years.
  4. Cox proportional hazard models were used to calculate HRs with age as the time metric. Adjusted for smoking (never, quit $10 y ago, quit 5-9 y ago, quit 1-4 y ago, quit ,1 y ago, or current and smokes #20 or .20 cigarettes/d), energy (continuous), energy-adjusted total fat (continuous), and sex (in sex- combined models). Duration of overweight by diabetes, P-interaction = 0.01. Cumulative overweight by diabetes, P-interaction = 0.02. 4 Quintiles for years overweight and cumulative OWY were based on the distribution of the cohort who ever had overweight with a separate category for never overweight. Weighted cumulative OWY (similar to pack-years) are based on the degree of overweight over time.
  5. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005;92:2076-83.
  6. Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, Albanes D. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005;294:2872-8.
  7. Michaud DS, Wolpin B, Giovannucci E, Liu S, Cochrane B, Manson JE, Pollak MN, Ma J, Fuchs CS. Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Bio- markers Prev 2007;16:2101-9.
  8. Anderson KE, Mack TM, Silverman DT. Cancer of the Pancreas. In: Schottenfeld D, Fraumeni JF, eds. Cancer epidemiology and pre- vention. 3rd ed. New York, NY: Oxford University Press, 2006:721-63.
  9. Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML, Abbruzzese JL. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009;301:2553-62.
  10. Schatzkin A, Subar AF, Thompson FE, Harlan LC, Tangrea J, Hollenbeck AR, Hurwitz PE, Coyle L, Schussler N, Michaud DS, et al. Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American As- sociation of Retired Persons Diet and Health Study. Am J Epidemiol 2001;154:1119-25.
  11. Michaud DS, Midthune D, Hermansen S, Leitzmann M, Harlan LC, Kipnis V, Schatzkin A. Comparison of cancer registry case ascertain- ment with SEER estimates and self-reporting in a subset of the NIH- AARP Diet and Health Study. J Registr Manag 2005;32:70-5.
  12. WHO Expert Committee. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995;854:1-452.
  13. Spiegelman D, Hertzmark E, Wand HC. Point and interval estimates of partial population attributable risks in cohort studies: examples and software. Cancer Causes Control 2007;18:571-9.
  14. Lin G, So Y, Johnston G. Analyzing survival data with competing risks using SAS software. SAS Global Forum 2012. Cary, NC: SAS Institute, 2012.
  15. Andersen PK, Geskus RB, de Witte T, Putter H. Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol 2012;41:861-70.
  16. Eberle CA, Bracci PM, Holly EA. Anthropometric factors and pan- creatic cancer in a population-based case-control study in the San Francisco Bay area. Cancer Causes Control 2005;16:1235-44.
  17. Fryzek JP, Schenk M, Kinnard M, Greenson JK, Garabrant DH. The association of body mass index and pancreatic cancer in residents of southeastern Michigan, 1996-1999. Am J Epidemiol 2005;162:222-8.
  18. Ji BT, Hatch MC, Chow WH, McLaughlin JK, Dai Q, Howe GR, Gao YT, Fraumeni JF Jr. Anthropometric and reproductive factors and the risk of pancreatic cancer: a case-control study in Shanghai, China. Int J Cancer 1996;66:432-7.
  19. Urayama KY, Holcatova I, Janout V, Foretova L, Fabianova E, Adamcakova Z, Ryska M, Martinek A, Shonova O, Brennan P, et al. Body mass index and body size in early adulthood and risk of pan- creatic cancer in a central European multicenter case-control study. Int J Cancer 2011;129:2875-84.
  20. Patel AV, Rodriguez C, Bernstein L, Chao A, Thun MJ, Calle EE. Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2005;14:459-66.
  21. Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001;286:921-9.
  22. Levi Z, Kark JD, Afek A, Derazne E, Tzur D, Furman M, Gordon B, Barchana M, Liphshitz I, Niv Y, et al. Measured body mass index in adolescence and the incidence of pancreatic cancer in a cohort of 720,000 Jewish men. Cancer Causes Control 2012;23:371-8.
  23. Genkinger JM, Spiegelman D, Anderson KE, Bernstein L, van den Brandt PA, Calle EE, English DR, Folsom AR, Freudenheim JL, Fuchs CS, et al. A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer 2011;129:1708-17.
  24. WCRF/AICR. Continuous update project for pancreatic cancer. World Cancer Research Fund 2012. Available from: http://www.dietandcancerreport. org/cup/current_progress/pancreatic_cancer.php (cited December 2012).
  25. Bao B, Wang Z, Li Y, Kong D, Ali S, Banerjee S, Ahmad A, Sarkar FH. The complexities of obesity and diabetes with the development and pro- gression of pancreatic cancer. Biochim Biophys Acta 2011;1815:135-46.
  26. Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A. Ab- normal glucose metabolism and pancreatic cancer mortality. JAMA 2000;283:2552-8.
  27. Stattin P, Bjor O, Ferrari P, Lukanova A, Lenner P, Lindahl B, Hallmans G, Kaaks R. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007;30:561-7.
  28. Grote VA, Rohrmann S, Nieters A, Dossus L, Tjonneland A, Halkjaer J, Overvad K, Fagherazzi G, Boutron-Ruault MC, Morois S, et al. Diabetes mellitus, glycated haemoglobin and C-peptide levels in re- lation to pancreatic cancer risk: a study within the European Pro- spective Investigation into Cancer and Nutrition (EPIC) cohort. Diabetologia 2011;54:3037-46.
  29. Grote VA, Rohrmann S, Dossus L, Nieters A, Halkjaer J, Tjonneland A, Overvad K, Stegger J, Chabbert-Buffet N, Boutron-Ruault MC, et al. The association of circulating adiponectin levels with pancreatic cancer risk: a study within the prospective EPIC cohort. Int J Cancer 2012;130:2428-37.
  30. Hennig R, Ding XZ, Adrian TE. On the role of the islets of Langerhans in pancreatic cancer. Histol Histopathol 2004;19:999-1011.
  31. Bell RH Jr, McCullough PJ, Pour PM. Influence of diabetes on suscep- tibility to experimental pancreatic cancer. Am J Surg 1988;155:159-64.
  32. Pour PM, Kazakoff K, Carlson K. Inhibition of streptozotocin-induced islet cell tumors and N-nitrosobis(2-oxopropyl)amine-induced pan- creatic exocrine tumors in Syrian hamsters by exogenous insulin. Cancer Res 1990;50:1634-9.
  33. Pour PM, Stepan K. Modification of pancreatic carcinogenesis in the hamster model. VIII. Inhibitory effect of exogenous insulin. J Natl Cancer Inst 1984;72:1205-8.
  34. Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Standop J, Ding XZ, Adrian TE, Pour PM. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001;120:1263-70.
  35. Zyromski NJ, Mathur A, Gowda GA, Murphy C, Swartz-Basile DA, Wade TE, Pitt HA, Raftery D. Nuclear magnetic resonance spectros- copy-based metabolomics of the fatty pancreas: implicating fat in pancreatic pathology. Pancreatology 2009;9:410-9.
  36. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Metformin and cancer risk in diabetic patients: a sys- tematic review and meta-analysis. Cancer Prev Res (Phila) 2010;3: 1451-61.
  37. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol 2012;107:620-6.
  38. Klopp AH, Zhang Y, Solley T, Amaya-Manzanares F, Marini F, Andreeff M, Debeb B, Woodward W, Schmandt R, Broaddus R, et al. Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. Clin Cancer Res 2012;18:771-82.
  39. Bellows CF, Zhang Y, Chen J, Frazier ML, Kolonin MG. Circulation of progenitor cells in obese and lean colorectal cancer patients. Cancer Epidemiol Biomarkers Prev 2011;20:2461-8.
  40. Zhang Y, Daquinag A, Traktuev DO, Amaya-Manzanares F, Simmons PJ, March KL, Pasqualini R, Arap W, Kolonin MG. White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Cancer Res 2009;69:5259-66.
  41. Berrington de Gonzalez A, Spencer EA, Bueno-de-Mesquita HB, Roddam A, Stolzenberg-Solomon R, Halkjaer J, Tjonneland A, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, et al. Anthropometry, physi- cal activity, and the risk of pancreatic cancer in the European Pro- spective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2006;15:879-85.
  42. Arslan AA, Helzlsouer KJ, Kooperberg C, Shu XO, Steplowski E, Bueno-de-Mesquita HB, Fuchs CS, Gross MD, Jacobs EJ, Lacroix AZ, et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consor- tium (PanScan). Arch Intern Med 2010;170:791-802.
  43. Stolzenberg-Solomon RZ, Adams K, Leitzmann M, Schairer C, Michaud DS, Hollenbeck A, Schatzkin A, Silverman DT. Adiposity, physical ac- tivity, and pancreatic cancer in the National Institutes of Health-AARP Diet and Health Cohort. Am J Epidemiol 2008;167:586-97.
  44. Aune D, Greenwood DC, Chan DS, Vieira R, Vieira AR, Navarro Rosenblatt DA, Cade JE, Burley VJ, Norat T. Body mass index, ab- dominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol 2012;23:843-52.
  45. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999- 2010. JAMA 2012;307:491-7.
  46. Verhage BA, Schouten LJ, Goldbohm RA, van den Brandt PA. An- thropometry and pancreatic cancer risk: an illustration of the impor- tance of microscopic verification. Cancer Epidemiol Biomarkers Prev 2007;16:1449-54.
  47. Klipstein-Grobusch K, Kroke A, Boeing H. Reproducibility of self- reported past body weight. Eur J Clin Nutr 1998;52:525-8.
  48. Perry GS, Byers TE, Mokdad AH, Serdula MK, Williamson DF. The validity of self-reports of past body weights by U.S. adults. Epidemi- ology 1995;6:61-6.
  49. Stevens J, Keil JE, Waid LR, Gazes PC. Accuracy of current, 4-year, and 28-year self-reported body weight in an elderly population. Am J Epidemiol 1990;132:1156-63.
  50. Kovalchik S. Validity of adult lifetime self-reported body weight. Public Health Nutr 2009;12:1072-7.
  51. Kyulo NL, Knutsen SF, Tonstad S, Fraser GE, Singh PN. Validation of recall of body weight over a 26-year period in cohort members of the Adventist Health Study 2. Ann Epidemiol 2012;22:744-6.
  52. Norgan NG, Cameron N. The accuracy of body weight and height recall in middle-aged men. Int J Obes Relat Metab Disord 2000;24:1695-8.
  53. Casey VA, Dwyer JT, Coleman KA, Krall EA, Gardner J, Valadian I. Accuracy of recall by middle-aged participants in a longitudinal study of their body size and indices of maturation earlier in life. Ann Hum Biol 1991;18:155-66.
  54. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999- 2010. JAMA 2012;307:483-90.